[ Price : $8.95]
CDERs 10th yearly drug safety report highlights the FY 2024 establishment of two new units contributing to drug safety.[ Price : $8.95]
Canadian researchers find that 16% of patients in Phase 2 oncology trials receive treatments that are later approved by FDA for th...[ Price : $8.95]
FDA clears an Abanza 510(k) for its WasherCap Mini fixation system for soft tissue repair, including meniscal root repair and ante...[ Price : $8.95]
FDA accepts for review a Regeneron Pharmaceuticals BLA resubmission for odronextamab in relapsed/refractory follicular lymphoma.[ Price : $8.95]
GenBioPro, which manufactures FDA-approved generic mifepristone, says it wants to be added to the list of defendants in a suit see...[ Price : $8.95]
Fresh on the heels of staff disruptions caused by the termination of about 1,000 probationary employees, the Trump administration ...[ Price : $8.95]
FDA warns San Diego, CA-based Fertility Center of California about deviations from regulations governing cells, tissues, and cellu...[ Price : $8.95]
FDA accepts for priority review a Merck supplemental BLA for Keytruda (pembrolizumab) for treating patients with resectable locall...